Literature DB >> 32383278

Risk factors and treatment outcomes of peristomal pyoderma gangrenosum in patients with inflammatory bowel disease.

Jingzhou Wang1, Joshua Prenner2, Wenfei Wang1, Atsushi Sakuraba3, Neil Hyman4, Sushila Dalal3, Roger Hurst4, Russell D Cohen3, Konstantin Umanskiy4, Benjamin D Shogan4, Lindsay Alpert5, David T Rubin3, Janice Colwell4, Joel Pekow3.   

Abstract

BACKGROUND: Insufficient data exist for peristomal pyoderma gangrenosum (PPG), which primarily affects patients with inflammatory bowel disease (IBD). AIMS: To evaluate the risk factors and treatment response of PPG in IBD patients in a real-life cohort.
METHODS: Cases of PPG were identified retrospectively using ICD-9/10 codes in patients with IBD who had an ostomy at a tertiary care centre. Disease-specific characteristics were compared between groups with and without PPG, and response to therapy was evaluated in patients with PPG.
RESULTS: The cohort included 41 IBD patients with PPG and 123 IBD controls with an ostomy who never developed PPG. Patients with PPG were more likely to be female (76% vs 51%, P = 0.006), had higher BMIs (29.78 ± 0.89 vs 23.53 ± 0.51, P < 0.0001) and had increased usage of pouch belts (97% vs 71%, P = 0.0008) compared to controls. There were no differences in age at surgery (41.76 ± 2.60 vs 43.49 ± 1.50, P = 0.57) or IBD diagnosis (63% vs 54% Crohn's disease, P = 0.28) between PPG and controls. 85% of PPG patients achieved complete resolution with different treatments, including surgery. Complete resolution with topical corticosteroids and calcineurin inhibitors alone were low (14% and 13% respectively). Higher rates of complete resolution were reported with anti-tumour necrosis factor (TNF) agents (63%) and surgical interventions (80%).
CONCLUSIONS: Female gender, higher BMI and pouch belts were associated with increased risk of developing PPG. Most PPG cases resolved after treatment with the highest rates of complete resolution seen with anti-TNF agents and surgical intervention.
© 2020 John Wiley & Sons Ltd.

Entities:  

Year:  2020        PMID: 32383278     DOI: 10.1111/apt.15766

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  2 in total

Review 1.  Vedolizumab and Extraintestinal Manifestations in Inflammatory Bowel Disease.

Authors:  Jurij Hanzel; Christopher Ma; Niels Vande Casteele; Reena Khanna; Vipul Jairath; Brian G Feagan
Journal:  Drugs       Date:  2021-01-05       Impact factor: 9.546

2.  Diagnosis and Treatment Difficulty in Early-Onset Peristomal Pyoderma Gangrenosum Associated With Ulcerative Colitis: A Case Report.

Authors:  Ken Imaizumi; Hiroyuki Kasajima; Kazutoshi Terashima; Naoe Furukawa; Kazuaki Nakanishi
Journal:  Cureus       Date:  2022-02-20
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.